tradingkey.logo

Dare Bioscience Inc <DARE.OQ> expected to post a loss of 58 cents a share - Earnings Preview

ReutersMay 9, 2025 9:23 PM
  • Dare Bioscience Inc DARE.OQ DARE.O is expected to show a rise in quarterly revenue when it reports results on May 13 for the period ending March 31 2025

  • The San Diego California-based company is expected to report a 3,233.3% increase in revenue to $300 thousand from $9 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Dare Bioscience Inc is for a loss of 58 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Dare Bioscience Inc is $13.00​, above​ its last closing price of $2.92. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.53

-0.65

Missed

-21.9

Sep. 30 2024

-0.76

-0.73

-0.55

Beat

25

Jun. 30 2024

-0.65

0.00

1.52

Beat

Mar. 31 2024

-0.72

-0.72

-0.84

Missed

-16.7

​​Dec. 31 2023

-1.60

-1.18

-0.72

Beat

38.8

Sep. 30 2023

-1.16

-1.18

-1.08

Beat

8.2​

Jun. 30 2023

-1.21

-1.18

-1.20

Missed

-1.7

Mar. 31 2023

-1.22

-1.20

-1.08

Beat

10

This summary was machine generated May 9 at 21:23 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI